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Abstract: Bladder cancer, one of the more common cancers, is a heterogeneous disease, both morphologically and clinically. Although
histological classification and extent of the disease (staging) guide treatment options, the heterogeneity in responses to therapy
highlights the need for better stratification of patients for the appropriate therapy in order to achieve better outcomes. Several molecular
classifications of muscle-invasive bladder cancer have been proposed but currently their use in clinical practice is limited by the
complexity of the methods used and diversity of the subtypes.
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Bladder cancer is among the most prevalent and deadly
cancers with approximately 550K new cases and 200K
deaths in 2018 worldwide. Although there have been some
advances in treatments over the years, there is still a need
for a more refined and tailored (targeted) therapy options.
The vast majority of bladder cancers are of urothelial
origin. The classification of urothelial tumours in
the recent 2016 World Health Organization (WHO)
Classification of Tumours of the Urinary System and Male
Genital Organs in part parallels the dual track concept
of carcinogenesis [1]. Most urothelial carcinomas have a
papillary architecture and do not invade the bladder wall.
Classified as noninvasive papillary urothelial carcinomas,
they are treated by local excision and bladder preserving
intravesical therapies. Although some of these tumours
progress as invasive tumours, most recur as noninvasive
tumours. Since standard long-term management entails
periodic cystoscopies with biopsies, as needed, bladder
cancer is one of the most expensive cancers to treat. A
major challenge is to find effective treatment strategies
for high grade, high stage invasive tumours for which the
current 5-year survival rate ranges between 36%, when
there are lymph node metastasis, and 5% for distant
metastasis.
Urothelial carcinomas are histomorphologically
dissimilar. Due to the inherent plasticity of the urothelium,
urothelial carcinomas include many histologic variants,
such as micropapillary, plasmacytoid/diffuse/signet
ring, lipoid, etc., as well as different states of histologic
differentiations, i.e. squamous and glandular. The variant

morphologies guide some therapeutic decisions. However,
for many tumours precise targetable markers predictive of
response to a specific therapy have not been identified.
In recent years molecular characterizations of urothelial
carcinoma [2–4] have defined subtypes of muscle invasive
cancer that respond differently to current chemotherapy
regimens [5]. These studies showed that muscle invasive
bladder cancer (MIBC) has a high mutation rate similar
to that of melanoma and nonsmall cell lung cancers. One
limitation is that the data have been derived from largely
nonoverlapping data sets, using different methods and
resulting in multiple nomenclatures for the subtypes.
In order to achieve an international consensus on the
MIBC molecular subtypes, the latest study [6] analysed
the published classification schemes and further stratified
previously defined categories of luminal and basal (similar
to the breast carcinoma) into 6 distinct subtypes: luminalpapillary (LumP), luminal nonspecified (LumNS), luminal
unstable (LumU), stroma-rich, basal/squamous (Ba/Sq),
and neuroendocrine-like (NE-like).
Each subtype has distinctive molecular features,
progression-risk and responsiveness to specific systemic
drugs.
· LumP subtype (24%) is enriched in the noninvasive
(pTa) phenotype (papillary architecture with low risk
for progression) and is strongly associated with FGFR3
transcriptional activity. These tumours may respond to
neoadjuvant cisplatin-based chemotherapy as well as to
pan-FGFR inhibitor agents, i.e. infigratinib, irrespective of
the mutation or translocation status of FGFR3.

* Correspondence: fvakar@uw.edu

This work is licensed under a Creative Commons Attribution 4.0 International License.

1677

VAKAR LOPEZ et al. / Turk J Med Sci
· The LumNS (formerly known as “luminal infiltrated”)
subtype (8%) has an elevated stromal infiltration signature,
mainly myofibroblastic. It also expresses CD274 (PD-L1)
and CTLA4 markers, defining a phenotype that is reported
to respond to immune checkpoint therapy (atezolizumab).
· The LumU subtype (15%) is a recently defined
category characterized by expression of luminal markers
(uroplakins) as well as by KRT20 and SNX31. Being a
new category, no therapy response information has been
acquired or reported.
· Stroma-rich subtype (15%) has intermediate levels of
urothelial differentiation. This subtype is also characterized
by stromal infiltration with overexpression of smooth
muscle, endothelial, fibroblast, and myofibroblast gene
signatures as well as overexpression of mainly B- and
T-cell markers.
· The Bas/Sq subtype (35%), more often seen in women
than in men, exhibits squamous differentiation and
expresses basal keratin(s) and immune markers (cytotoxic
lymphocytes and natural killer cells). Both cisplatin-based
neoadjuvant chemotherapy (NAC) and immune therapy
are appropriate treatment options for this subtype.
· The sixth subtype NE-like (3%) expresses
neuroendocrine and neuronal genes and has a high
proliferative state. Concurrent TP53 and RB1 inactivation
is common in NE-like tumours. As in neuroendocrine
neoplasms arising in other sites, these tumours may benefit
from etopside-cisplastin therapy.
Although subtype-specific personalized therapies could
optimize patient outcomes, the subtype-drug correlation

needs to be verified in prospective studies before they can
be integrated into clinical practice. Hurdles to widespread
implementation of subtyping bladder carcinoma include
the difficulty of obtaining high quality RNA and the
labour and cost of microarray analyses with expertise in
bioinformatics.
A possible solution to these hurdles is identifying
subtype-specific markers that can be more easily and
readily detected by immunohistochemistry (IHC) using
analyte-specific primary antibodies which reflect the
molecular subtypes.
Several studies [7,8] compared the performance of
antibody panels (composed of 5 to 28 antibodies) and
with the transcriptome profiles of the same cohort of
analytes. The results showed that GATA3 and CK5/6
identified luminal and basal subtypes, respectively, with
91% accuracy based on transcriptome analysis. Using
a panel of 28 antibodies, the Lund group [8] showed
that some tumours of different IHC-defined groups
clustered together; conversely, some of the IHC-defined
groups clustered separately. These discrepancies may be
due to contamination of samples by nontumour cells in
the transcriptome and/or interpatient and intra-patient
tumour heterogeneity.
Currently, there is not enough evidence to molecularly
or phenotypically subtype bladder cancers. However,
the proposed molecular and/or immunohistochemical
subtyping could be used for building a framework for
prospective hypothesis generation and hypothesis testing
in clinical trials.
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